NASDAQ:PRPH - ProPhase Labs Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.0268 -0.04 (-1.30 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$3.0268
Today's Range$3.02 - $3.0450
52-Week Range$2.01 - $6.64
Volume9,524 shs
Average Volume8,811 shs
Market Capitalization$34.91 million
P/E Ratio3.93
Dividend YieldN/A
Beta0.03
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.

Receive PRPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRPH
CUSIPN/A
Phone215-345-0919

Debt

Debt-to-Equity RatioN/A
Current Ratio28.70
Quick Ratio26.87

Price-To-Earnings

Trailing P/E Ratio3.93
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.87 million
Price / Sales3.54
Cash Flow$1.2205 per share
Price / Cash2.48
Book Value$2.66 per share
Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$41.83 million
Net Margins-22.15%
Return on Equity-6.86%
Return on Assets-6.51%

Miscellaneous

Employees46
Outstanding Shares11,530,000
Market Cap$34.91

The Truth About Cryptocurrencies

ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions

What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?

ProPhase Labs declared a special dividend on Wednesday, May 9th. Stockholders of record on Monday, May 21st will be given a dividend of $1.00 per share on Tuesday, June 5th. The ex-dividend date is Friday, May 18th. View ProPhase Labs' Dividend History.

How will ProPhase Labs' stock buyback program work?

ProPhase Labs announced that its board has authorized a stock buyback program on Saturday, November 11th 2017, which authorizes the company to buyback 1,700,000 shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through a tender offer. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs (NASDAQ:PRPH) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million for the quarter. ProPhase Labs had a negative net margin of 22.15% and a negative return on equity of 6.86%. View ProPhase Labs' Earnings History.

When is ProPhase Labs' next earnings date?

ProPhase Labs is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for ProPhase Labs.

What is the consensus analysts' recommendation for ProPhase Labs?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of ProPhase Labs' key competitors?

Who are ProPhase Labs' key executives?

ProPhase Labs' management team includes the folowing people:
  • Mr. Ted William Karkus, Chairman and Chief Exec. Officer (Age 59)
  • Ms. Monica Brady, Principal Financial Officer & Chief Accounting Officer (Age 41)

Has ProPhase Labs been receiving favorable news coverage?

Media stories about PRPH stock have trended somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProPhase Labs earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the company an impact score of 46.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of ProPhase Labs?

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $3.0268.

How big of a company is ProPhase Labs?

ProPhase Labs has a market capitalization of $34.91 million and generates $9.87 million in revenue each year. ProPhase Labs employs 46 workers across the globe.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]


MarketBeat Community Rating for ProPhase Labs (NASDAQ PRPH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote "Outperform" if you believe PRPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.